The influence of glucose-lowering therapies on cancer risk in type 2 diabetes.
about
Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trialsRisk of cancer in diabetes: the effect of metforminRole of insulin in the type 2 diabetes therapy: past, present and futureTargeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitusTargeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitusTargeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitusDiabetes and gastric cancer: the potential linksValidating drug repurposing signals using electronic health records: a case study of metformin associated with reduced cancer mortalityThe Role of Common Pharmaceutical Agents on the Prevention and Treatment of Pancreatic CancerMetformin Is Associated With Slightly Reduced Risk of Colorectal Cancer and Moderate Survival Benefits in Diabetes Mellitus: A Meta-AnalysisObesity and cancer: mechanistic insights from transdisciplinary studiesDiabetes and cancer: two diseases with obesity as a common risk factorInsulin therapy and risk of prostate cancer: a systematic review and meta-analysis of observational studiesMetformin therapy and risk of cancer in patients with type 2 diabetes: systematic reviewLink between type 2 diabetes and Alzheimer's disease: from epidemiology to mechanism and treatmentThe metabolic and mitogenic properties of basal insulin analoguesMetformin and the risk of cancer: time-related biases in observational studiesInsulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients: a systemic review and meta-analysisCellular and molecular mechanisms of metformin: an overviewChemopreventive drugs: mechanisms via inhibition of cancer stem cells in colorectal cancerThe association between type 2 diabetes mellitus and women cancer: the epidemiological evidences and putative mechanismsDiabetes and cancer: a consensus report.The effect of environmental chemicals on the tumor microenvironmentMetformin in obesity, cancer and aging: addressing controversiesMetformin downregulates the insulin/IGF-I signaling pathway and inhibits different uterine serous carcinoma (USC) cells proliferation and migration in p53-dependent or -independent mannersLow concentrations of metformin selectively inhibit CD133⁺ cell proliferation in pancreatic cancer and have anticancer actionImpact of glucose-lowering agents on the risk of cancer in type 2 diabetic patients. The Barcelona case-control study14-Year risk of all-cause mortality according to hypoglycaemic drug exposure in a general populationMetformin as an adjuvant drug against pediatric sarcomas: hypoxia limits therapeutic effects of the drugDose-Dependent AMPK-Dependent and Independent Mechanisms of Berberine and Metformin Inhibition of mTORC1, ERK, DNA Synthesis and Proliferation in Pancreatic Cancer CellsEffect of metformin on cancer risk and treatment outcome of prostate cancer: a meta-analysis of epidemiological observational studiesAssociation between Gastroenterological Malignancy and Diabetes Mellitus and Anti-Diabetic Therapy: A Nationwide, Population-Based Cohort StudyEvolution of primary care databases in UK: a scientometric analysis of research outputMolecular characterisation of long-acting insulin analogues in comparison with human insulin, IGF-1 and insulin X10The maternal womb: a novel target for cancer prevention in the era of the obesity pandemic?Exposure to excess insulin (glargine) induces type 2 diabetes mellitus in mice fed on a chow diet.A metabolic perturbation by U0126 identifies a role for glutamine in resveratrol-induced cell death.Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model.Lipotoxicity disrupts incretin-regulated human β cell connectivityA framework for the in vitro evaluation of cancer-relevant molecular characteristics and mitogenic potency of insulin analogues.
P2860
Q21144611-E99F843D-7F7B-4C30-AA31-A3CE5D1C137EQ21284807-E85BB1B8-82A7-4B28-B02A-57A3AE84693CQ22241148-23F1AB69-76A2-4CA7-90D0-0408DB5B382BQ24186667-5F619F64-1619-4445-BB0B-6F9F2BE6C39AQ24202505-EAC2FFC9-F9AE-47B7-B325-550BDCC7CC70Q24236456-3BB92B48-57C3-43AC-8FE9-AA86825B3E49Q24602836-8E64710B-8002-4037-B86F-1F89F6F6153AQ24745996-0DAEF690-00E5-4A38-99F4-49C400EC2254Q26738873-8B89AFB4-58BD-4B99-85AB-6617839D3DB6Q26765139-72B77118-5C2C-47F3-91B7-B0358716BAF7Q26786829-12D9981F-CAF1-4192-A0E8-8B02B574156AQ26822753-1CB9CD76-B810-48BF-98A2-4957F72CE497Q26823071-F0AB155C-E54C-4895-9890-03D5A43ED016Q26850912-E7BC5691-8F14-40BA-8A83-34BD85F20AD4Q26860246-BE7C9DB1-8D00-4D86-82E3-939091B2D73AQ26991486-43149728-28E8-49D4-94E3-0F973A268544Q26999266-81235BA6-A7D7-4FD0-8F5E-DE45D63E32DAQ27008886-F498047A-A933-45BC-A50F-715C07B736B6Q27013561-2B1ADD06-B23C-4E74-A380-BB7DEFABB45CQ27026428-31901C01-D031-4246-A988-70B498D4FF7FQ27026813-3076E904-8697-4145-A80F-19630F22655DQ27686977-0609348D-25BE-4BC6-B980-788D5A0162F8Q28085138-C9294E7B-DA93-471B-9E49-82D1732E8929Q28480735-17926BED-2DD6-4F71-9BD3-8296436A29F0Q28486318-B983A54F-17CC-4DFA-8507-029968ECB4DBQ28487772-AD7349F6-4449-4A54-B74A-E302EA4D7A81Q28535372-CE899583-2A22-4A59-AC97-B9D8BFAAEF55Q28538095-00FD24C3-D851-4B1B-BC6F-9BDF17A27F4CQ28538155-5672911A-86FC-45BF-B071-89FA1A686D0AQ28542653-3C7D0C4D-0921-4302-87DA-8A5EB4C751B0Q28542914-D457F8DD-AFC4-44B6-BAEA-3D9244C8F7ABQ28547270-60631015-8F7D-47D2-90C3-5FE5423666E7Q28552854-D821803E-FD50-4C8C-9DA4-E95EF23FBD01Q28730070-9986A5EA-38FD-4C45-A4FE-065ABF7C32F7Q30404178-DF8D3889-17B3-4F16-B6E6-F34620993BE0Q30412619-E1D4E373-F4D9-4123-8F73-D2F7D2785DD4Q30423585-30122438-8D55-4406-A46B-D16BA7A1CAF7Q30513617-516A7B19-C8A0-4A1A-8F63-A421E4B89509Q30634760-4D66E840-62E6-4885-8FCB-6370F0DADAD0Q30662831-7F5B4D34-7850-4DFB-90E0-A31F5B08A005
P2860
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes.
@ast
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes.
@en
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes.
@nl
type
label
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes.
@ast
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes.
@en
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes.
@nl
prefLabel
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes.
@ast
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes.
@en
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes.
@nl
P2093
P1433
P1476
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes.
@en
P2093
P2888
P304
P356
10.1007/S00125-009-1440-6
P577
2009-07-02T00:00:00Z
P5875
P6179
1041996770